-
Activist Investor Nelson Peltz's Fund Buys Stake In Unilever: FT
Sunday, January 23, 2022 - 4:10pm | 282Trian Fund Management LP, the activist hedge fund run by Nelson Peltz, has built a stake in Unilever PLC (NYSE: UL), the Financial Times reports, citing people with direct knowledge of the matter. The $8.5 billion New York-based hedge fund has taken a position in shares of the British...
-
GlaxoSmithKline PLC Looks To Continue To Trade Above Its Annual-High Share Price Today
Wednesday, August 18, 2021 - 1:31pm | 673The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. GlaxoSmithKline PLC (NYSE: GSK) traded at a new 52-week high today of $42.68. This new high was reached on below-average trading volume as...
-
Consult Your Doctor: FDA Thinks Big Pharma Might Be Intentionally Confusing You With Too Much Information
Thursday, June 1, 2017 - 8:40am | 887You’ve seen the commercials: The antidepressant — oh, let’s call it Realitor — may cause suicide, explosive bowel syndrome, an erection lasting more than 72 days, lethargy, lumbago, listeria, hysteria, projectile vomiting and perhaps the plague. Consult your doctor if...
-
#PreMarket Primer: Thursday, December 4: Beige Book Paints Positive Picture Of U.S. Economy
Thursday, December 4, 2014 - 9:34am | 1300The Federal Reserve’s “beige book” report struck an optimistic tone and indicated that the U.S. central bank saw improving economic growth through 2015. The report showed that U.S. firms added a “sizable” number of new jobs, but that wage growth was minimal. The...
-
#PreMarket Primer: Wednesday, May 14: Markets Surprised To Hear Bundesbank Is On Board With ECB Stimulus
Wednesday, May 14, 2014 - 7:02am | 1192Investors were surprised by reports from The Wall Street Journal which claimed that Germany’s Bundesbank is on board for more stimulus measures at the European Central Bank’s June meeting if the region’s financials warrant action. The bank, which has traditionally been at odds with the ECB over...
-
Pharmaceutical Stocks For Income, Value And Growth Investors
Thursday, April 17, 2014 - 10:12am | 357Pharmaceutical stocks are excellent holdings in times of a downturn. Health care is the largest component of the American economy, about one-sixth the gross domestic product. For income, value, and growth investors, respectively, there are GlaxoSmithKline (NYSE: GSK), Pfizer (NYSE: PFE), and...
-
AstraZeneca to Acquire Pearl Therapeutics to Gain Foothold into Lucrative Market (AZN, GSK, NVS)
Monday, June 10, 2013 - 9:18am | 503AstraZeneca (NYSE: AZN) announced Monday that it will purchase privately held Pearl Therapeutics for up to $1.15 billion in its continuing drive to reinvigorate its product pipeline. The acquisition of the U.S. based respiratory drug specialist Pearl gives AstraZeneca a foothold in the newest...
-
Likely Winners and Losers in Obama's 2014 Budget
Thursday, April 11, 2013 - 10:21am | 646President Barack Obama’s proposed $3.8 trillion budget is designed to cut the deficit by $600 billion over 10 years, after factoring in the negation of cuts already enacted under the sequester according to The Associated Press. Depending on the framework of the final budget, some businesses...
-
Calls Bought on Exelixis (EXEL)
Thursday, June 3, 2010 - 1:45pm | 124Shares of Exelixis (NASDAQ: EXEL) are higher on the session by 6.47%, currently trading $5.43. The stock is popping today after the company said they were going to raise $160 million to repay obligations under a loan from GlaxoSmithKline. Options traders are coming after calls in the name with the...
-
FDA Asks Doctors To Suspend Use Of GlaxoSmithKline (GSK) Rotavirus Vaccine
Monday, March 22, 2010 - 3:37pm | 132The U.S. Food and Drug Administration announced on Monday that the agency has asked doctors to stop giving the GlaxoSmithKline PLC (NYSE: GSK) Rotarix vaccine on a temporary basis because extraneous viral components have been found in the vaccine. The GlaxoSmithKline PLC Rotarix vaccine is given to...
-
XenoPort (XNPT) Shares Fall 65% After FDA Rejection
Thursday, February 18, 2010 - 8:56pm | 139Shares of XenoPort, Inc. (Nasdaq: XNPT) crashed today after the pharmaceutical company received word from the FDA that it would not approve the company's development stage drug called Horizant, which XenoPort developed with partner GlaxoSmithKline Plc (NYSE: GSK). The FDA said that pancreatic tumor...
-
GlaxoSmithKline (GSK) Shares Rise With Upgrade
Tuesday, February 16, 2010 - 12:28pm | 83Shares of GlaxoSmithKline PLC (NYSE: GSK) were up more than 1% in morning trading after the company was upgraded by JP Morgan (NYSE: JPM) from Underweight to Neutral with a price target of $26. The pharmaceutical company is adding 200 employees to its field force and is introducing several new...